Bio-Rad Labs (BIO) Posts Q4 Loss of $0.70/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results
February 23, 2017 4:27 PM ESTHERCULES, CA -- (Marketwired) -- 02/23/17 -- Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2016.
Fourth-quarter 2016 reported revenues were $571.5 million, an increase of 0.2 percent compared to $570.6 million reported for the fourth quarter of 2015. On a currency-neutral basis, quarterly revenues increased 0.8 percent compared to the same period in 2015. Fourth-quarter gross margin was 55.0 percent compared to 54.1 percent during the fourth quarter in 2015.
Life Science... More
